Biotech Values

[jq1234]

I don’t think one needs to listen to them now to know it was chaotic. You leaned positive previously so it might be new to you . I knew that already from their various data presentations, constant shifting explanations, and then top them all with CMC issue revelation - you knew CMC issue as major already - which is why our main takeaways from JPM call are different.

I don’t have much expectation from NKTR really, if they could update RCC data from PIVOT-02 confirming melanoma CR argument - only thing left really at this point - it could provide something positive, if no update one has to assume negative like NSCLC they told you already. I never heard WL in any previous cc before, he seemed better than others. I think it rests with BMY now. It seems BMY has put its act together by taking more active role. Let’s see how this new dose “optimization” go. Also have to watch Roche and THOR data this year, the better their data the more negative for bempeg.